Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Ronawk logo — Ronawk’s Bio-OS™ will do for biological manufacturing what N...

Ronawk

Ronawk’s Bio-OS™ will do for biological manufacturing what Nvidia™ GPUs did for AI computing.

Founded 2019 United States Overland Park, United States 17 employees Series A Total: $9.89M Biopharma, Biotechnology +1

General Information

Company Name Ronawk
Founded Year 2019
Location United States Overland Park, United States
Employees 17
Industries Biopharma, Biotechnology, Health Care
Funding Stage Series A
Business Model B2B, SaaS, Platform
Revenue Model Subscription, Licensing, Usage Based
Social

BounceWatch is an independent company data service, not affiliated with Ronawk. To contact Ronawk, visit ronawk.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Ronawk compare?

A PDF of Ronawk and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Ronawk soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Ronawk

Ronawk, founded in 2019 and headquartered in the United States, is revolutionizing the biopharma industry with its innovative Bio-OS™ platform. This biological operating system aims to transform biological manufacturing much like Nvidia™ GPUs did for AI computing.

By addressing the shortcomings of existing cell culture tools, which were primarily designed for microbes, Ronawk offers a compelling solution. Bio-OS™ consists of three integrated layers: modular hardware, standardized software, and living wetware. This trifecta enables a conducive environment for various cells, yielding predictable results for researchers and scalable pathways for manufacturers to develop future therapies.

Operating at the intersection of Biopharma, Biotechnology, and Health Care, Ronawk empowers the next wave of therapeutic innovation. The company recently secured a $6.50M Series A investment in August 2023, underscoring its potential and attractiveness to investors seeking to tap into the future of biotechnological advancements.

Business keywords: Biological Manufacturing, Stem Cell Expansion, 3D Cell Culture, Biologics Production, Patient-Specific Therapies, Tissue Engineering, 3D Bioprinting, Regenerative Medicine, Personalized Medicine, Modular Hardware, Standardized Software, Living Wetware, Cellular Reprogramming, Biological Characterization, Life Sciences

Services & Products

Bio-OS Platform Development
Continuous Cell Production
Controlled Tissue Assembly
Biological Diagnostics
Biological Engineering

Target Customers

Biotechnology Companies Pharmaceutical Companies Research Institutions Biomedical Engineering Firms

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $6.50M -
01 Aug 2023
Seed $1.89M -
01 Feb 2023
Seed $1.50M 1
avpict
01 Jul 2022
Support Program Undisclosed 1
MassChallenge
MassChallenge
01 Jul 2021
Early VC Undisclosed -
01 Jun 2020

Ronawk Alternatives & Competitors

View All Alternatives
Ronawk vs
PUR Biologics
PUR Biologics United States

The Authority in Ortho and Spinal Biologics

2 employees
Biotechnology, Health Care
Ronawk vs
Aglaris Ltd Group
Aglaris Ltd Group United Kingdom

Aglaris Ltd. together with Aglaris Cell, Changing Cellular Manufacturing: More productive, more reli...

Grant
11 employees
Biotechnology, Health Care
Ronawk vs
Angiocrine Bioscience, Inc.
Angiocrine Bioscience, Inc. United States

Transforming medicine through engineered cellular therapies that restore, regenerate, and repair tis...

Grant
21 employees
Biotechnology, Health Care
View all alternatives

FAQ About Ronawk

Ronawk’s Bio-OS™ will do for biological manufacturing what Nvidia™ GPUs did for AI computing.
Ronawk was founded in 2019.
Ronawk is headquartered in Overland Park, United States.
Ronawk operates in Biopharma, Biotechnology and Health Care. Its work centres on Biological Manufacturing, Stem Cell Expansion, 3D Cell Culture and Biologics Production. Its customers include Biotechnology Companies, Pharmaceutical Companies and Research Institutions.
Ronawk has a B2B, SaaS and Platform business model. Its revenue comes from Subscription, Licensing and Usage Based.
Ronawk has approximately 17 employees.
Ronawk has completed 5 funding rounds, raising a total of $9.89M. The latest funding stage is Series A.
Ronawk offers: Bio-OS Platform Development, Continuous Cell Production, Controlled Tissue Assembly, Biological Diagnostics, Biological Engineering.
Top alternatives and competitors to Ronawk include PUR Biologics, Aglaris Ltd Group, Angiocrine Bioscience, Inc., VIDEREGEN LIMITED, Akron Bio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Ronawk and PUR Biologics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Ronawk, https://bouncewatch.com/company/ronawk, updated 11 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes